Get the Stockscreener App
72.38
1.59%
1.13
After Hours:
72.40
0.02
+0.03%
Dexcom Inc stock is traded at $72.38, with a volume of 4.60M.
It is up +1.59% in the last 24 hours and down -0.66% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$71.25
Open:
$71.3
24h Volume:
4.60M
Relative Volume:
0.83
Market Cap:
$27.93B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
30.96
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
+3.43%
1M Performance:
-0.66%
6M Performance:
+3.56%
1Y Performance:
-12.72%
1-Day Range:
$69.74
$72.77
1-Week Range:
$67.30
$72.77
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.38 | 25.99B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom: The Growth Thesis Still Needs To Be Proven - Seeking Alpha
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom G7 CGM sensoraccessory that makes stacking multiple days easier - AD HOC NEWS
Enterprise value to revenue forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
DXCMDexcom Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Investors to Connect - The National Law Review
Devon Energy Wolfcamp development programshale wells drive long-term output - AD HOC NEWS
Is DexCom Inc (DXCM) a Bargain After 3.8% Drop? GF Value Says Un - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom G7 Professional from Dexcom Inc.Clinic-first CGM for short-term wear - AD HOC NEWS
DXCM ALERT: Securities Fraud Class Action Launched Against DexCom, Inc.December 26, 2025 Deadline - The National Law Review
Did FDA-Backed Stelo Expansion Beyond Insulin Users Just Shift DexCom's (DXCM) Investment Narrative? - Sahm
Enterprise value to EBITDA forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to sales forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to book forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Redefining CGM for people with type 2 diabetes: Dexcom announces Dexcom Flex in Germany - MSN
Price to earnings forward of DexCom, Inc. – SIX:DXCM - TradingView
Devon Energy expands Permian drilling plan, shares tied to oil price swings - AD HOC NEWS
Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)Recover - The National Law Review
DexCom, Inc. (DXCM) Investor Outlook: Seizing a 21.53% Upside in the Booming CGM Market - DirectorsTalk Interviews
Dexcom Inc. extends Stelo reach, shares in focus on NASDAQ - AD HOC NEWS
DexCom Continues Push Towards Universal Glucose Biosensing with Latest AdvancesEarnings Risk Report - dars.gov.et
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All - Insider Monkey
Did You Lose Money on DexCom, Inc. (DXCM)? Levi & Korsinsky Urges Investors to Act Before December 26, 2025 - The National Law Review
Join Class Action to Recover Losses from DexCom, Inc. (DXCM)Contact Levi & Korsinsky Before December 26, 2025 - The National Law Review
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. InvestorsLead Plaintiff Deadline December 26, 2025 - The National Law Review
Recover Investment Losses: Class Action Initiated Against DexCom, Inc. (DXCM) - The National Law Review
Deutsche Bank Names Top Healthcare Stocks Led by DexCom and Insulet - Investing.com Canada
Dexcom G7 from Dexcom Inc.smaller sensor, quicker warm-up and app-first thinking - Ad-hoc-news.de
The STACK oil gathering system from Devon Energy Corp.quietly critical for getting barrels to mar - Ad-hoc-news.de
DexCom (DXCM) Stock After Three-Year 45% Slide Is The Market Too Pessimistic - Yahoo Finance
Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market - Kavout | AI
Dexcom Inc launches redesigned Stelo app, shares trade around key Nasdaq level - Ad-hoc-news.de
DexCom, Inc. Actuals & Estimates (NASDAQ:DXCM) - TradingView
Devon Energy consensus steady, shares track U.S. oil peers - Ad-hoc-news.de
DexCom, Inc. Actuals & Estimates (HAN:DC4) - TradingView
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now? - The Globe and Mail
Dexcom reports clear analyst support, shares trade below new Deutsche Bank target - Ad-hoc-news.de
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dexcom Inc (DXCM) Institutional Confidence - TradingKey
DexCom (DXCM) Launches New Stelo App As It Expands Into Four Countries - Sahm
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DexCom, Inc. Actuals & Estimates (FWB:DC4) - TradingView
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
DexCom Inc. (NASDAQ:DXCM): Why Healthcare Is Watching? - Kalkine Media
DexCom, Inc. Actuals & Estimates (SIX:DXCM.USD) - TradingView
DXCM Forecast — Price Target — Prediction for 2027 - TradingView
Dexcom alerts users after stolen G7 sensors allegedly sold by unauthorized distributor - Class Action Lawsuits
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans - The Globe and Mail
Dexcom - Forbes
Dexcom Inc (DXCM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dexcom Inc Stock (DXCM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FOLETTA MARK G | Director |
Jun 15 '26 |
Sale |
74.13 |
4,000 |
296,540 |
52,852 |
1.51%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):